









Markets
/
Stocks
/
nasdaq-glmd
/

Galmed Pharmaceuticals Ltd

GLMD



View Detailed Chart

1.460USD

-0.050-3.31%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

7.74MMarket Cap

LossP/E TTM



Galmed Pharmaceuticals Ltd

1.460

-0.050-3.31%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

-3.31%

5 Days

-3.31%

1 Month

+2.46%

6 Months

-35.40%

Year to Date

-54.23%

1 Year

-82.62%

View Detailed Chart

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

249 / 506

Overall Ranking

407 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Fairly Valued

The company’s latest PE is -0.17, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 135.24K shares, increasing 13.36% quarter-over-quarter.